dianthustherapeutics
Senior Clinical Trial Associate
At a Glance
- Location
- Remote
- Work Regime
- remote
- Experience
- 5+ years
- Posted
- 2026-04-02T10:55:19-04:00
Key Requirements
Required Skills
Domain Knowledge
- Biotech
- Clinical
- Medical
- Pharmaceutical
- Regulatory
Requirements
Minimum of 5 years’ experience working on clinical studies in pharmaceutical, biotech, or CRO setting preferred.
Knowledge of global regulatory and compliance requirements for clinical research.
Experience with essential documentation for Trial Master Files required.
Knowledge of drug development, clinical operation processes, medical terminology, and procedures according to FDA GCP/ICH regulatory guidelines.
Experience working with clinical trial systems (CTMS, IRT, EDC) preferred.
Responsibilities
We are building our Clinical team and need two Senior Clinical Trail Associates who are open to owning end-to-end processes.
You will report directly to the respective Senior Director, Clinical Development Operations global leads.
As the Senior Clinical Trial Associate (Sr.
Associate, you will play a crucial role in the Clinical Development Operations (CDO) department to support the planning, execution, and management of clinical trials in accordance with regulatory requirements and industry best practices. In this role, you will collaborate with cross functional study teams, clinical Research Organizations (CROs), and other external vendors to ensure the successful delivery of clinical study activities.
You must have experience supporting global clinical study teams in order to be successful.
Provides support to assigned clinical studies, taking on various responsibilities to support project and study deliverables.
About the Company
We are developing potentially best in class therapies for patients living with severe autoimmune diseases. Our lead antibody, claseprubart (DNTH103), is purposefully engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein that drives disease pathology – enabling less frequent and more convenient self-administered subcutaneous injections. Our second clinical candidate, DNTH212 is a first and potentially best in class, bifunctional inhibitor that targets clinically validated and complementary disease modifying mechanisms, Type 1 IFN suppression and B cell modulation – enabling potential for improved clinical outcomes and patient friendly convenient, self-administered subcutaneous injections. To learn more, please visit
www.dianthustx.com
and follow us on
.